Search results for "Cytotoxic"

showing 10 items of 1673 documents

A sphingosine kinase inhibitor combined with temozolomide induces glioblastoma cell death through accumulation of dihydrosphingosine and dihydroceram…

2014

AbstractGlioblastomas (GBMs) are very aggressive tumors with low chemosensitivity. The DNA-alkylating agent temozolomide (TMZ) is currently the most efficient chemotoxic drug for GBM therapy; however, many patients develop resistance to TMZ. Combining TMZ with another agent could present an improved treatment option if it could overcome TMZ resistance and avoid side effects. Sphingosine kinase inhibitors (SKIs) have emerged as anticancer agents. Sphingosine kinases are often overexpressed in tumors where their activity of phosphorylating sphingosine (Sph) contributes to tumor growth and migration. They control the levels of the pro-apoptotic ceramide (Cer) and Sph and of the pro-survival sp…

Cancer ResearchCeramideProgrammed cell deathImmunologySphingosine kinaseAntineoplastic AgentsApoptosisBiologyCeramidesCellular and Molecular Neurosciencechemistry.chemical_compoundSphingosineCell Line TumorAutophagyTemozolomideHumansEnzyme InhibitorsCytotoxicitySphingosineCell DeathKinaseBrain NeoplasmsAutophagyCell BiologyEndoplasmic Reticulum StressCell biologyDacarbazinePhosphotransferases (Alcohol Group Acceptor)chemistryApoptosisDrug Resistance NeoplasmCancer researchDrug Therapy CombinationOriginal ArticleGlioblastomaCell deathdisease
researchProduct

Abstract LB-243: Cetuximab and Artesunate synergistically inhibit the invasion and distant metastasis of non-small cell lung cancer

2012

Abstract Cancer is a complex disease and multi step process evolving from malfunctions of molecules and their complex networks which regulate this process. The blockage of the cancer signalling network is crucial in the cancer treatment. In some cases, single drug therapy might not be comprehensive enough to inhibit the activity of secondary signals, feedback regulations and resistance to particular molecules, due to their abundant expression or activity. An understanding of these complex phenomena in cancer therapy for the benefit of patients is essential, especially since it bears the chance to establish novel concepts of combination drug therapy. In the present study, we have tried to fi…

Cancer ResearchCetuximabbiologybusiness.industryCell growthCancermedicine.diseasePrimary tumorMetastasisOncologyImmunologymedicineCancer researchbiology.proteinCytotoxic T cellEpidermal growth factor receptorLung cancerbusinessmedicine.drugCancer Research
researchProduct

Cytotoxic effects of chemotherapy on cancer and immune cells: how can it be modulated to generate novel therapeutic strategies?

2015

The first objective to use chemotherapy is to kill cancer cells. However, it is common knowledge that these drugs can also damage healthy host cells, especially immune cells, and thus impair the endogenous antitumor response. Here, we focus on the cytotoxic effects of chemotherapy on tumor cells and immune cells. It is not enough to simply kill cancer cells, and causing immunogenic cell death will impair the adaptive immune system's ability to fight the remaining cancer cells. On the other hand, the killing of immune cells can also enhance tumor growth. A study of the repercussions of the cytotoxic effects of chemotherapy is of great importance to evaluate the antitumor response. Strategie…

Cancer ResearchChemotherapybusiness.industrymedicine.medical_treatmentCancerchemical and pharmacologic phenomenaGeneral MedicineSuicide genemedicine.diseaseAcquired immune systemImmune systemOncologyImmunologyCancer cellMedicineImmunogenic cell deathCytotoxic T cellbusinessFuture Oncology
researchProduct

Analysis of antigens recognized on human melanoma cells by A2-restricted cytolytic t lymphocytes (CTL)

1993

We have pursued our analysis of potential tumor-rejection antigens recognized on human melanoma by autologous cytolytic T lymphocytes (CTL). We reported previously that 3 distinct antigens (A,B,C) were recognized on melanoma cell line SK29-MEL in association with HLA-A2. Selection for melanoma-cell variants resistant to anti-A CTL revealed that antigen A consists of at least 2 determinants (Aa, Ab) which can be lost separately. Genetic linkage between Aa and Ab was suggested by concomitant loss of Aa and Ab in an immunoselected tumor-cell variant. This variant was also resistant to an autologous CTL clone restricted by HLA-B45, indicating that this CTL may also recognize a determinant of an…

Cancer ResearchClone (cell biology)T lymphocyteBiologyCytotoxicity Tests ImmunologicTransfectionVirologyEpitopesCytolysisCTL*OncologyLytic cycleAntigenAntigens NeoplasmHLA-B AntigensHLA-A2 AntigenGene expressionImmunologyTumor Cells CulturedHumansCloning MolecularCytotoxicityMelanomaT-Lymphocytes CytotoxicInternational Journal of Cancer
researchProduct

Impact of Extracellular Acidity on the Activity of P-glycoprotein and the Cytotoxicity of Chemotherapeutic Drugs

2006

AbstractThe expression and activity of P-glycoprotein (pGP) play a role in the multidrug resistance of tumors. Because solid-growing tumors often show pronounced hypoxia or extracellular acidosis, this study attempted to analyze the impact of an acidic environment on the expression and activity of pGP and on the cytotoxicity of chemotherapeutic agents. For this, prostate carcinoma cells were exposed to an acidic extracellular environment (pH 6.6) for up to 24 hours. pGP activity was more than doubled after 3 to 6 hours of incubation in acidic medium, whereas cellular pGP expression remained constant, indicating that increased transport rate is the result of functional modulation. In paralle…

Cancer ResearchDaunorubicinPharmacologyP-glycoproteinlcsh:RC254-282Calcium in biologyExtracellularmedicinepolycyclic compoundsintracellular Ca2+ concentrationCytotoxicityacidityProtein kinase CP-glycoproteinbiologyintegumentary systemChemistrychemotoxicitylcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogenscarbohydrates (lipids)BiochemistryCell culturebiology.proteinIntracellularmedicine.drugprotein kinase CNeoplasia
researchProduct

Cleavage of CD95 by matrix metalloproteinase-7 induces apoptosis resistance in tumour cells

2004

The ability of tumour cells to resist apoptosis-inducing signals by cytotoxic T cells may decide the success or failure of tumour elimination. An important effector of apoptosis is the CD95/CD95 ligand system (APO-1/Fas) that mediates perforin-independent cytotoxic T-cell killing of tumour cells. We propose a new strategy by which tumour cells can resist CD95-induced apoptosis. We identified matrix metalloproteinase-7, MMP-7 (Martilysin), as the first physiologically relevant protease that can specifically cleave CD95. MMP-7 is of unique importance because it is produced by the tumour cells themselves at early stages of tumour development. Microsequencing of the positions in CD95 cleaved by…

Cancer ResearchEffectorApoptosishemic and immune systemschemical and pharmacologic phenomenaBiologyMatrix metalloproteinaseFas receptorCleavage (embryo)medicine.disease_causeCell biologyApoptosisMatrix Metalloproteinase 7hemic and lymphatic diseasesTumor Cells CulturedGeneticsExtracellularmedicineHumansCytotoxic T cellfas Receptorbiological phenomena cell phenomena and immunityCarcinogenesisMolecular BiologyOncogene
researchProduct

Tumoricidal activity of endothelium-derived NO and the survival of metastatic cells with high GSH and Bcl-2 levels.

2008

Metastatic spread, not primary tumor burden, is the leading cause of cancer death. Glutathione (L-gamma-glutamyl-L-cysteinyl-glycine; GSH) is the most prevalent non-protein thiol in mammalian cells, and in cancer cells is particularly relevant in regulating mutagenic mechanisms, DNA synthesis, growth, and multidrug and radiation resistance. In malignant tumors, as compared with normal tissues, that resistance associates in most cases with higher GSH levels. Interaction of metastatic cells with the vascular endothelium activates local release of proinflammatory cytokines, which act as signals promoting cancer cell adhesion, extravasation, and proliferation. A high% of metastatic cells with h…

Cancer ResearchEndotheliumPhysiologyCell SurvivalClinical BiochemistryBiologyNitric OxideBiochemistryNitric oxideProinflammatory cytokinechemistry.chemical_compoundmedicineCytotoxic T cellHumansEndotheliumNeoplasm MetastasisGlutathionemedicine.diseasePrimary tumorGlutathioneExtravasationmedicine.anatomical_structurechemistryBiochemistryProto-Oncogene Proteins c-bcl-2Cancer cellCancer researchNitric oxide : biology and chemistry
researchProduct

Overlapping peptides of melanocyte differentiation antigen melan-A/MART-1 recognized by autologous cytolytic T lymphocytes in association with HLA-B4…

1998

From the peripheral blood lymphocytes (PBLs) of melanoma patient SK29(AV) we have previously isolated 2 independent cytolytic T lymphocyte (CTL) clones (CTL7/147 and CTL13/211), which lysed autologous tumor cells in association with HLA-B45.1. As demonstrated here, both CTL clones were directed against melanocyte differentiation antigen Melan-A/MART-1, which also was recognized by HLA-A2.1-restricted CTLs from the same patient. By generating and transfecting 3'-deletion mutants of Melan-A/MART-1 cDNA, we localized its peptide-coding regions. The HLA-B45.1-presented peptides were derived from a hydrophobic region of the protein and largely overlapped the peptides recognized by CTLs from the …

Cancer ResearchEpitopes T-LymphocytePeptideHuman leukocyte antigenBiologyEpitopeMART-1 AntigenMelanocyte differentiationAntigenAntigens NeoplasmHLA-A2 AntigenTumor Cells CulturedAnimalsHumansAmino Acid SequenceMelanomachemistry.chemical_classificationBase SequenceSequence Homology Amino AcidDNA NeoplasmT lymphocyteVirologyNeoplasm ProteinsCTL*OncologychemistryHLA-B AntigensCOS CellsClone (B-cell biology)T-Lymphocytes CytotoxicInternational Journal of Cancer
researchProduct

The new iodoacetamidobenzofuran derivative TR120 decreases STAT5 expression and induces antitumor effects in imatinib-sensitive and imatinib-resistan…

2013

The identification of novel compounds modulating the expression/activity of molecular targets downstream to BCR-ABL could be a new approach in the treatment of chronic myeloid leukemias (CMLs) resistant to imatinib or other BCR-ABL-targeted molecules. Recently, we synthesized a new class of substituted 2-(3,4,5-trimethoxybenzoyl)-2-N,N-dimethylamino-benzo[b]furans, and among these 3-iodoacetylamino-6-methoxybenzofuran-2-yl(3,5-trimethoxyphenyl)methanone (TR120) showed marked cytotoxic activity in BCR-ABL-expressing cells. Interestingly, TR120 was more potent than imatinib in cell growth inhibition and apoptosis induction in both BCR-ABL-expressing K562 and KCL22 cells. Moreover, it showed a…

Cancer ResearchFusion Proteins bcr-ablApoptosisPiperazinesSettore MED/15 - Malattie Del Sanguechemistry.chemical_compoundhemic and lymphatic diseasesSTAT5 Transcription FactorCytotoxic T cellPharmacology (medical)Cyclin D1STAT5biologyDrug SynergismCell cycleNeoplasm ProteinsGene Expression Regulation NeoplasticLeukemiaOncologyProto-Oncogene Proteins c-bcl-2BenzamidesImatinib MesylateGrowth inhibitionmedicine.drugbcl-X ProteinDown-RegulationAntineoplastic AgentsBone Marrow CellsResting Phase Cell CycleColony-Forming Units AssayBenzophenonesNecrosisCell Line TumorLeukemia Myelogenous Chronic BCR-ABL PositivemedicineHumansneoplasmsBenzofuransPharmacologyG1 PhaseImatinibBCR-ABL chronic myeloid leukemia imatinib resistance STAT5 tyrosine kinase inhibitorsmedicine.diseaseSettore CHIM/08 - Chimica FarmaceuticaGenes bcl-1Genes bcl-2PyrimidineschemistryApoptosisDrug Resistance NeoplasmSettore BIO/14 - FarmacologiaCancer researchbiology.proteinK562 CellsK562 cells
researchProduct

Induction of immunogenicity of a human renal-cell carcinoma cell line byTAP1-gene transfer

1999

Reduced expression of the major-histocompatibility-complex(MHC)-class-I antigens has been demonstrated in renal-cell carcinoma (RCC), and appeared to be associated with deficiencies in the expression and function of different components of the MHC-class-I-antigen-processing pathway and poor recognition by cytotoxic T-lymphocytes (CTL). In order to investigate the role of peptide transporters for the immunogenic phenotype of RCC, tumor cells were stably transfected with the human TAP1A gene. While the TAP1 transfectants showed heterogeneous TAP1-transgene expression pattern of mRNA and protein, high TAP1 expression and a TAP-controlled increase in MHC-class-I surface expression could be achi…

Cancer ResearchGenetic transferTransfectionBiologyurologic and male genital diseasesMajor histocompatibility complexImmune toleranceImmune systemOncologyAntigenCell cultureImmunologyCancer researchbiology.proteinCytotoxic T cellInternational Journal of Cancer
researchProduct